Roche at CTAD 2026
Nov 16–19, 2026 Boston, MA ~1.7k attendees Website
Roche takes part in 6 sessions at CTAD 2026 in Boston. Its program centres on trontinemab, its Brainshuttle anti-amyloid antibody, and on NLRP3 inflammasome inhibition. Its work covers pharmacodynamic and imaging results from the Brainshuttle AD study and the design of the TARBELA-AD phase 2 trial.
| Organization | CTAD 2026 Attendance |
|---|---|
Roche Basel, Switzerland | |
Swiss drugmaker developing trontinemab, a Brainshuttle anti-amyloid antibody in phase 3 for early Alzheimer's disease. | Poster Mon Nov 16 – Tue Nov 17 2:00pm Mon – 5:30pm Tue Talk Mon Nov 16 4:50pm–5:30pm Talk Mon Nov 16 4:50pm–5:30pm Talk Tue Nov 17 9:10am–9:35am Talk Tue Nov 17 2:35pm–3:15pm |
Instantly find 20 buyers from Roche
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the CTAD Conference. Organization details are derived from CTAD’s published program, poster list and sponsor page. Submit a correction